Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

JANX - Janux Therapeutics Inc


IEX Last Trade
47.03
2.390   5.082%

Share volume: 423,888
Last Updated: Fri 30 Aug 2024 09:59:59 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$44.64
2.39
5.35%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
8%
Profitability 0%
Dept financing 3%
Liquidity 75%
Performance 1%
Company vs Stock growth
vs
Performance
5 Days
2.31%
1 Month
13.95%
3 Months
-6.80%
6 Months
0.83%
1 Year
345.73%
2 Year
323.62%
Key data
Stock price
$47.03
P/E Ratio 
-55.64
DAY RANGE
N/A - N/A
EPS 
-$0.90
52 WEEK RANGE
$5.65 - $65.60
52 WEEK CHANGE
$3.27
MARKET CAP 
2.451 B
YIELD 
N/A
SHARES OUTSTANDING 
52.164 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/05/2024
BETA 
2.06
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$300,954
AVERAGE 30 VOLUME 
$475,027
Company detail
CEO: David Alan Campbell
Region: US
Website: januxrx.com
Employees: 9
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

janux therapeutics is an innovative biopharmaceutical company developing next-generation therapeutics based on its proprietary tumor activated t cell engager (tractr) platform technology to better treat patients suffering from cancer. janux’s initial focus is on developing a novel class of t cell engagers (tces), and its lead product candidates are designed to target clinically validated drug targets. while tce therapeutics have displayed potent anti-tumor activity in hematological cancers, developing tces to treat solid tumors have faced challenges due to the limitations of prior tce technologies, namely (i) overactivation of the immune system leading to cytokine release syndrome, (ii) on-target, healthy tissue toxicities, and (iii) poor pharmacokinetics leading to short half-life. janux is using its tractr platform technology to engineer product candidates designed to overcome these limitations. janux is developing a broad pipeline with lead programs targeting prostate-specific membr

Recent news